Pharmaxis Ltd (ASX:PXS)'s Gary Phillips speaks to Proactive following the news its novel topical drug treatment for scarring has delivered positive phase 1 clinical trial results and will now advance to the next stage of development in patients. He says in a study of healthy volunteers PXS‐6302 demonstrated good tolerability and full inhibition of the enzymes being targeted to prevent scarring.
Pharmaxis hails positive results in Phase 1 scarring trial
